Daehan Nupharm Co.,Ltd. (054670.KQ) Stock

054670.KQ logo

Daehan Nupharm Co.,Ltd.

054670.KQSouth Korea
Healthcare

Company profile

Daehan Nupharm reported revenue of 202.40 billion KRW for fiscal year 2025, up 0.1% from fiscal year 2024, and net income of 15.26 billion KRW. That is a net profit margin of 7.5% for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 204.22 billion KRW in fiscal year 2023 to 202.40 billion KRW in fiscal year 2025, 0.4% a year on average.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Daehan Nupharm Co.,Ltd.

Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products. The company also provides animal health and nutrition products; health supplements; and aesthetic/medical devices. The company was formerly known as Daehan New Pharm Co., Ltd and changed its name to Daehan Nupharm Co.,Ltd. in March 2025. Daehan Nupharm Co.,Ltd. was founded in 1984 and is headquartered in Hwaseong-si, South Korea.

Largest shareholders

  • Wan-Jin Lee26.53 %26.53%
  • Won-Seok Lee8.271 %8.27%
  • Sung-sook Choi2.462 %2.46%
  • Daehan Nupharm Co.,Ltd.2.23%
  • Avent Korea Co., Ltd.1.97%

Share of the company, as of September 25, 2026

Leadership

  • Wonseok Lee — CEO & Executive Director
  • Jeong-Su Choi — Executive Director & Head of Finance Department, 58
  • Sang-Ho Park — Executive Director & Head of Business Management Division, 58
  • Dong-Hoon Yang — Executive Director & Head of New Business Division, 57
  • YeongDong Kim — Executive Director & Head of Overseas Business Division, 56

How much revenue does Daehan Nupharm make?

Daehan Nupharm reported 202.40 billion KRW in revenue for fiscal year 2025, up 0.1% from 202.19 billion KRW in fiscal year 2024.

What companies are similar to Daehan Nupharm?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Withus Pharmaceutical Co.,LTD. (330350.KQ), Korea Pharma Co., Ltd. (032300.KQ), Sinil Pharmaceutical Co., Ltd. (012790.KQ), PharmGen Science, Inc. (004720.KS).

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
HeadquartersHwaseong-si, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
66 Pharmaceutical Complex 1-gil, Hwaseong-si, 18622
Phone
82 3 1778 2600
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Daehan Nupharm Co.,Ltd. (054670.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/054670.KQ

LinkedInLinkedInXXYouTubeYouTube